Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies
C. van Herpen(AstraZeneca (United Kingdom)), Giuseppe Giaccone(Cornell University), O. Saunders(AstraZeneca (United Kingdom)), Joachim Drevs(AstraZeneca (United Kingdom)), Ute Zirrgiebel(Johannes Gutenberg University Mainz), Emile E. Voest(University Medical Center Utrecht), Clemens Unger(AstraZeneca (United Kingdom)), C.J.A. Punt(Amsterdam University Medical Centers), Jane Robertson(Cancer Research UK), Hester van Cruijsen
Cited by 10
Related Papers
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2009|913
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
The Integrated Genomic Landscape of Thymic Epithelial Tumors
|Cancer Cell|2018|389